Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension

Abstract

This randomised, double-blind study was designed to investigate the efficacy of a once-daily (OD) combination of the AT 1 receptor blocker, eprosartan 600 mg, and the thiazide diuretic, hydrochlorothiazide (HCTZ) 12.5 mg, in patients with mild to moderate hypertension (sitting diastolic blood pressure (sitDBP) у98 mm Hg and р114 mm Hg) not adequately controlled with eprosartan 600 mg OD. A total of 494 patients entered the open-label monotherapy run-in phase, which consisted of eprosartan 600 mg OD for 3 weeks. Patients who responded to monotherapy were not eligible to enter the randomised phase of the study and were withdrawn. The remaining 309 patients were then randomised to either eprosartan 600 mg plus HCTZ 12.5 mg OD or to continue on eprosartan 600 mg OD. In the eprosartan plus HCTZ combination group, both sitDBP and sitting systolic blood pressure (sitSBP) were significantly

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

“…Changes in StaSBP paralleled those of SitSBP, with considerable reductions after monotherapy as well as combination therapy. These data are consistent with previously published data for eprosartan and eprosartan plus HCTZ in the general hypertensive population [11][12][13][14][15] and extend the efficacy and safety demonstration to eprosartan doses up to 1200 mg/ day either alone or in combination with the diuretic among older (460 years) patients. That trough to peak ratios of SBP were consistently near one at week 9 suggest that the once-daily dosing of eprosartan provides constant reduction of BP throughout the 24-h dosing period in these patients.…”

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

“…In the 9 trials assessing the impact of adding a thiazide diuretic to an ARB versus the diuretic alone, combination therapy reduced the systolic and diastolic BPs significantly greater than diuretic monotherapy (at equivalent doses) after 6 to 12 weeks (62–69, 77). In one trial the addition of 12.5 mg/day of hydrochlorothiazide (HCTZ) to candesartan 16 mg/day resulted in similar BP reductions as candesartan at 32 mg/day (61).…”

“…The ARB eprosartan was studied by Sachse et al who reported 65 out of 157 (41.4%) patients having an adverse event of which 19 were probably treatment-related in the eprosartan monotherapy group (600 mg/day) compared to 69 out of 152 (45.4%) patients of which 25 were probably treatment related in the eprosartan/HCTZ combination group (600/12.5 mg/day) (62). …”

Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide

“…[11] In particular, thiazide diuretics complement the BP-lowering properties of ARBs. [12][13][14][15][16][17][18] The efficacy of an antihypertensive drug regimen is generally reported as the mean reduction in SBP DBP compared with baseline, placebo, or another antihypertensive regimen. These complementary vasodilation and pharmacologic activities result in sustained reductions in SBP DBP that are greater than those achievable by a diuretic or ARB alone.…”